Evaluating the Benefits of a Third MMRV Vaccine Dose for Adults in Alberta
Is a Third Dose of Measles-mumps-rubella-(Varicella) Vaccine (MMR(V)) Vaccine Beneficial for the Adult Population in Alberta?
This study is trying to see if giving a third dose of the MMRV vaccine can boost the immune response in women who didn't have strong enough protection after their first two doses.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | University of Alberta Academic / other |
| Locations | 1 site (Edmonton, Alberta) |
| Trial ID | NCT05923970 on ClinicalTrials.gov |
What this trial studies
This observational study investigates whether a third dose of the measles-mumps-rubella-varicella (MMRV) vaccine can enhance immune responses in women who have low antibody levels after receiving the standard two doses. It focuses on assessing both humoral and cell-mediated immune responses to determine the effectiveness of additional vaccination in preventing infections. The study will not administer the vaccine but will analyze serological data from participants to understand their immune status better. The findings aim to clarify the protection levels in highly vaccinated populations, particularly concerning prenatal health risks.
Who should consider this trial
Good fit: Ideal candidates for this study are pregnant women who have undergone routine prenatal screening for rubella antibodies.
Not a fit: Patients who are younger than 18 years of age will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved vaccination strategies that enhance immunity in vulnerable populations, particularly pregnant women.
How similar studies have performed: While this approach is novel in assessing the need for a third dose in adults, similar studies have highlighted waning immunity in vaccinated populations, indicating a potential need for further investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women who are pregnant and have undergone routine prenatal screening for rubella antibodies. Exclusion Criteria: * Women younger than 18 years of age
Where this trial is running
Edmonton, Alberta
- University of Alberta — Edmonton, Alberta, Canada (Recruiting)
Study contacts
- Study coordinator: Carmen Charlton, PhD
- Email: carmen.charlton@albertahealthservices.ca
- Phone: 1 (780) 407-8975
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.